The use of Yttrium-90 Ibritumomab Tiuxetan ( 90 Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation
Jurczak, Wojciech, Kisiel, Elżbieta, Sawczuk-Chabin, Joanna, Centkowski, Piotr, Knopińska-Posłuszny, Wanda, Khan, OmeirVolume:
1
Year:
2015
Language:
english
Journal:
Współczesna Onkologia
DOI:
10.5114/wo.2015.50012
File:
PDF, 65 KB
english, 2015